甲氨蝶呤对大鼠脊髓挫伤急性期氧化损伤相关蛋白的影响

摘要/Abstract

摘要： 目的: 观察甲氨蝶呤(methotrexate, MTX)对大鼠脊髓挫伤急性期氧化损伤相关蛋白的影响,探讨其神经保护机制。方法: 采用连有 PinPoint^TM精密接触传感器的 Benchmark^TM立体定位颅脑撞击器制备脊髓挫伤大鼠模型。伤后 30 min,治疗组皮下注射MTX(0.5 mg/kg,按体质量计),对照组和假手术组注射等量生理盐水。术后1、3、6、12、24、48、72 h 进行动物采血和组织取材。采用酶联免疫吸附法检测血浆3-硝基酪氨酸(3-nitrotyrosine, 3-NT)的含量以及损伤组织晚期氧化蛋白产物(advanced oxidation protein products, AOPP)和蛋白羰基(protein carbonyl)的含量。结果: 术后各时间点,假手术组血浆中3-NT的含量以及组织中AOPP和蛋白羰基的含量均低于对照组。术后12~72 h,治疗组血浆中3-NT含量均显著低于对照组(P<0.05)。术后24~72 h,治疗组组织中AOPP含量均显著低于对照组(P<0.05)。但是,术后各时间点损伤组织中蛋白羰基的含量两组差异均无统计学意义。结论: MTX阻止脊髓继发性损伤可能与减少氧化损伤相关蛋白的形成有关。

关键词: 甲氨蝶呤, 脊髓挫伤, 急性期, 3-硝基酪氨酸, 晚期氧化蛋白产物, 蛋白羰基

Abstract: AIM: To examine the effect of methotrexate on spinal cord contusion-induced protein related with oxidative damage in rats at acute stage and to explore its neuroprotective mechanism. METHODS: Rat spinal cord contusion model was duplicated by a BenchmarkTM stereotaxic cortical impactor which connected with PinPoint? precision contact sensor. At posttraumatic 30 min, Treatment group was subcutaneously administrated methotrexate (0.5 mg/kg, according to the weight),Control group and Sham group were injected the same volume of physiological saline. At posttraumatic 1,3,6,12,24,48,72 h, blood and tissue samples were collected. ELISA method was used to determine the content of 3-nitrotyrosine (3-NT) in plasma,advanced oxidation protein products (AOPP) and protein carbonyl in injuried tissue. RESULTS: At all the time point after surgery, the contents of 3-NT, AOPP and protein carbonyl in Treatment group were lower than those in Control group. Post-traumatic 12h to 72 h, the contents of 3-NT in Treatment group were significantly lower than those in Control group (P<0.05). Post-traumatic 24 h to 72 h, the contents of AOPP in Treatment group were significantly lower than those in Control group (P<0.05). However, the content of protein carbonyl at each time point had no statistical significance between the two groups. CONCLUSION: The role of Methotrexate in preventing the secondary spinal cord injury may be related to reducing the formation of protein related with oxidative damage.

Key words: methotrexate, traumatic spinal cord injury, acute phase, 3-nitrotyrosine, advanced oxidation protein products, protein carbonyl

中图分类号:

张思, 顾兵, 李华南, 王烁宇, 张水印. 甲氨蝶呤对大鼠脊髓挫伤急性期氧化损伤相关蛋白的影响[J]. 中国临床药理学与治疗学, 2015, 20(1): 1-6.

ZHANG Si, GU Bing, LI Hua-nan, WANG Shuo-yu, ZHANG Shui-yin. Effect of methotrexate on spinal cord contusion-induced protein related with oxidative damage in rats at acute stage[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 1-6.

参考文献

[1] GhoshMitra S, Diercks DR, Mills NC, et al. Role of engineered nanocarriers for axon regeneration and guidance: current status and future trends[J]. Adv Drug Deliv Rev, 2012, 64(1): 110-125.
[2] Jia Z, Zhu H, Li J, et al. Oxidative stress in spinal cord injury and antioxidant-based intervention[J]. Spinal Cord, 2012, 50(4): 264-274.
[3] 肖寒贫,王烁宇,李华南,等. 脊髓损伤的临床药物治疗现状[J]. 神经药理学报, 2012, 2(2): 32-36.
[4] Kabel AM, Abdel-Rahman MN, El-Sisi Ael-D, et al. Effect of atorvastatin and methotrexate on solid Ehrlich tumor[J]. Eur J Pharmacol, 2013, 713(1/2/3): 47-53.
[5] 顾兵,金建波,李华南,等. 大鼠创伤性脊髓损伤模型的建立[J].中国临床药理学与治疗学,2011, 16(7): 721-728.
[6] 张思,王烁宇,李华南,等. 急性脊髓损伤后的氧化应激及其抗氧化治疗[J]. 神经药理学报, 2012, 2(3): 52-64.
[7] Panasenko OM, Gorudko IV, Sokolov AV. Hypochlorous Acid as a precursor of free radicals in living systems[J]. Biochemistry (Mosc), 2013, 78(13): 1466-1489.
[8] Hall ED. Antioxidant therapies for acute spinal cord injury[J]. Neurotherapeutics, 2011, 8(2): 152-167.
[9] Sullivan PG, Krishnamurthy S, Patel SP, et al. Temporal characterization of mitochondrial bioenergetics after spinal cord injury[J]. J Neurotrauma, 2007, 24(6): 991-999.
[10] Xiong Y, Rabchevsky AG, Hall ED. Role of peroxynitrite in secondary oxidative damage after spinal cord injury[J]. J Neurochem, 2007, 100(3): 639-649.
[11] Liu D, Shan Y, Valluru L, et al. Mn (III) tetrakis (4-benzoic acid) porphyrin scavenges reactive species, reduces oxidative stress, and improves functional recovery after experimental spinal cord injury in rats: comparison with methylprednisolone[J]. BMC Neurosci, 2013, 14: 23.
[12] Morsy MD, Mostafa OA, Hassan WN. A potential protective effect of alpha-tocopherol on vascular complication in spinal cord reperfusion injury in rats[J]. J Biomed Sci, 2010, 17: 55.
[13] Xiong Y, Hall ED. Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury[J]. Exp Neurol, 2009, 216(1): 105-114.
[14] Carrico KM, Vaishnav R, Hall ED. Temporal and spatial dynamics of peroxynitrite-induced oxidative damage after spinal cord contusion injury[J]. J Neurotrauma, 2009, 26(8): 1369-1378.
[15] Ersahin M, Özdemir Z, Özsavc1 D, et al. Melatonin treatment protects against spinal cord injury induced functional and biochemical changes in rat urinary bladder[J]. J Pineal Res, 2012, 52(3): 340-348.
[16] Quan HH, Kang KS, Sohn YK, Li M. Tempol reduces injury area in rat model of spinal cord contusion injury through suppression of iNOS and COX-2 expression[J]. Neurol Sci, 2013, 34(9): 1621-1628.
[17] Kesherwani V, Atif F, Yousuf S, Agrawal SK. Resveratrol protects spinal cord dorsal column from hypoxic injury by activating Nrf-2[J]. Neuroscience, 2013, 41: 80-88.
[18] Ormond DR, Peng H, Zeman R, et al. Recovery from spinal cord injury using naturally occurring antiinflammatory compound curcumin: laboratory investigation[J]. J Neurosurg Spine, 2012, 16(5): 497-503.
[19] Keith MP, Edison JD, Gilliland WR. Progress toward personalized treatment of rheumatoid arthritis[J]. Clin Pharmacol Ther, 2012, 92(4): 440-442.
[20] Shahin D, Toraby EE, Abdel-Malek H, et al. Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study)[J]. Clin Med Insights Arthritis Musculoskelet Disord, 2011, 4: 1-10.
[21] Kertmen H, Gürer B, Y1lmaz ER, et al. The protective effect of low-dose methotrexate on ischemia-reperfusion injury of the rabbit spinal cord[J]. Eur J Pharmacol, 2013, 714(1/2/3): 148-156.
[22] Asanuma H, Sanada S, Ogai A, et al. Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts[J]. J Cardiovasc Pharmacol, 2004, 43(4): 574-579.
[23] Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis[J]. Rheumatology (Oxford), 2008, 47(3): 249-255.
[24] Sanli AM, Serbes G, Sargon MF, et al. Methothrexate attenuates early neutrophil infiltration and the associated lipid peroxidation in the injured spinal cord but does not induce neurotoxicity in the uninjured spinal cord in rats[J]. Acta Neurochir (Wien), 2012, 154(6): 1045-1054.
[25] Yilmaz ER, Kertmen H, Dolgun H, et al. Effects of darbepoetin-α in spinal cord ischemia-reperfusion injury in the rabbit[J]. Acta Neurochir (Wien), 2012, 154(6): 1037-1043.
[26] Kajer TB, Fairfull-Smith KE, Yamasaki T, et al. Inhibition of myeloperoxidase- and neutrophil-mediated oxidant production by tetraethyl- and tetramethyl-nitroxides[J]. Free Radic Biol Med, 2014, 70:96-105.
[27] Chen Z, Tu S, Hu Y, et al. Prediction of response of collagen-induced arthritis rats to methotrexate: an (1)H-NMR-based urine metabolomic analysis[J]. J Huazhong Univ Sci Technolog Med Sci, 2012, 32(3): 438-443.
[28] Wang Z, Chen Z, Yang S, et al. (1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis[J]. Exp Ther Med, 2012, 4(1): 165-171.
[29] Bowman GL, Shannon J, Frei B, et al. Uric acid as a CNS antioxidant[J]. J Alzheimers Dis, 2010, 19(4): 1331-1336.
[30] Stinefelt B, Leonard SS, Blemings KP, et al. Free radical scavenging, DNA protection, and inhibition of lipid peroxidation mediated by uric acid[J]. Ann Clin Lab Sci, 2005, 35(1): 37-45.
[31] Hink HU, Fukai T. Extracellular superoxide dismutase, uric acid, and atherosclerosis[J]. Cold Spring Harb Symp Quant Biol, 2002, 67: 483-490.
[32] Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease[J]. Physiol Rev, 2007, 87(1): 315-424.
[33] Zheng Z, Guo X, Wei Q, et al. Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population[J]. Metab Brain Dis, 2014, 29(3):771-775.
[34] Zoccolella S, Tortorella C, Iaffaldano P, et al. Low serum urate levels are associated to female gender in multiple sclerosis patients[J]. PLoS One, 2012, 7(7): e40608.
[35] Pan M, Gao H, Long L, et al. Serum uric acid in patients with Parkinson's disease and vascular parkinsonism: a cross-sectional study[J]. Neuroimmunomodulation, 2013, 20(1): 19-28.
[36] Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression[J]. Mov Disord, 2010, 25(2): 224-228.
[37] Fang P, Li X, Luo JJ, et al. A Double-edged Sword: Uric Acid and Neurological Disorders[J]. Brain Disord Ther, 2013, 2(2): 109.
[38] Scott GS, Cuzzocrea S, Genovese T, et al. Uric acid protects against secondary damage after spinal cord injury[J]. Proc Natl Acad Sci U S A, 2005, 102(9): 3483-3488.
[39] Du Y, Chen CP, Tseng CY, et al. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity[J]. Glia, 2007, 55(5): 463-472.